General Hospital Of Ioannina G. Hatzikosta
- Address
- Makrigianni Street, 450 01 Ioannina, Greece
General Hospital Of Ioannina G. Hatzikosta - Cardiovascular Research Center
General Hospital Of Ioannina G. Hatzikosta is a prominent clinical research institution specializing in advanced cardiovascular disease investigation and novel therapeutic interventions. The center demonstrates particular expertise in conducting complex Phase 3 cardiovascular outcomes trials, focusing on life-threatening conditions that require innovative treatment approaches and specialized patient populations.
- Acute myocardial infarction management and self-administered emergency therapies
- Atrial fibrillation and stroke prevention in high-risk populations unsuitable for conventional anticoagulation
- Cardiovascular complications in end-stage kidney disease (ESKD) patients undergoing dialysis
The research center's portfolio emphasizes antiplatelet and anticoagulation therapies for cardiovascular protection, including pioneering work with novel agents such as P2Y12 inhibitors for acute coronary syndrome prevention and factor XIa inhibitors for stroke prevention. Their involvement in studies addressing atherosclerotic cardiovascular disease in ESKD patients demonstrates a comprehensive approach to managing complex cardiovascular risk factors, including inflammation reduction through anti-interleukin-6 therapy. This multidisciplinary focus positions the center at the forefront of cardiovascular research addressing unmet medical needs in challenging patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital Of Ioannina G. Hatzikosta
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects with End Stage Kidney Disease Undergoing Dialysis | CSL Behring LLC | Phase IV | Recruiting | Jul 2023 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Abelacimab | 1 | Unknown | 2023-10-31 | 2023-10-31 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.